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Abstract
Objective—We examined prevalence of substance use disorders (SUD) in women with: (1)
anorexia nervosa (AN) restricting type (RAN); (2) AN with purging only (PAN); (3) AN with binge
eating only (BAN); and (4) lifetime AN and bulimia nervosa (ANBN). Secondary analyses examined
SUD related to lifetime purging behavior and lifetime binge eating.
Method—Participants (N = 731) were drawn from the International Price Foundation Genetic
Studies.
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Results—The prevalence of SUD differed across AN subtypes, with more in the ANBN group
reporting SUD than those in the RAN and PAN groups. Individuals who purged were more likely to
report substance use than those who did not purge. Prevalence of SUD differed across lifetime binge
eating status.
Conclusion—SUD are common in AN and are associated with bulimic symptomatology. Results
underscore the heterogeneity in AN, highlighting the importance of screening for SUD across AN
subtypes.
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Strong evidence demonstrates that eating disorders and substance use disorders (SUD) co-
occur among individuals.1–5 The prevalence of drug and alcohol abuse is approximately 50%
in individuals with an eating disorder, compare with a prevalence of approximately 9% in the
general population.1 Similarly, among individuals with SUD, over 35% report having an eating
disorder compared with a 1–3% prevalence of eating disorders in the general population.1, 2
However, of theoretical importance is that among persons with some form of an eating disorder,
nicotine, alcohol, and illicit drug use are more common among those who binge eat.1 Thus,
inconsistencies across studies in reported rates of co-occurrence of eating disorders and SUD
3 along with inter-study differences in sample characteristics and general methodology may
partly influence this variation.
The suggestion of greater liability to drug use and abuse among persons who binge eat
compared to those with restricting type anorexia nervosa 2, 3, 4 is intriguing, if not
counterintuitive, in that among laboratory animals, food restriction enhances, while food-
satiation reduces, self-administration of nearly every licit and illicit substance with abuse
potential.5 Interestingly, risk of substance abuse may nevertheless be moderated by differences
in consummatory patterns across AN subtypes. Strober et al. 6 demonstrated that the 10-year
prospective risk of incident cases of SUD in persons hospitalized for AN was six-times greater
among individuals who reported binge eating while underweight compared with those with no
history of binge eating up to the time of index hospitalization. This risk was also associated
with elevated alcohol use disorder among first-degree relatives. Moreover, alcohol abuse
among those who developed binge eating subsequent to weight restoration did not differ
significantly from those who maintained a restricting profile throughout the study period. Bulik
et al. 7 similarly reported that alcohol use disorders were significantly more prevalent among
women with AN with binge eating compared with those with AN without binge eating,
although this pattern of results has not been universally replicated.8–11 Finally, little is known
regarding the extent to which purging behavior, in the absence of binge eating, 12, 13 is
associated with risk for SUD in AN.
The motivation for the current study stems from: 1) discrepancies in the extant literature
regarding the frequency with which lifetime SUD co-occurs with AN; 2) the dearth of studies
examining SUD across well-defined AN subtypes; 3) reported findings suggesting the need to
examine the extent to which SUD risk is exclusively associated with binge eating in the low
weight state;6 and 4) the importance of examining a purging-only subtype of AN 13 with
reference to SUD. To address these questions, the aims of the current study are: 1) to examine
the prevalence of SUD in a large sample of diagnostically well-categorized women with AN;
2) to compare the prevalence of SUD across AN subtypes; 3) to determine whether SUD are
more common in those who report binge eating in the underweight state compared to those
who develop binge eating at normal weight (i.e., not during episodes of AN); and, 4) to examine
the specific associations of SUD with binge eating and purging. A large international
collaboration involving sites in North America and Europe whose goal is to identify
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susceptibility genes associated with eating disorders 14 served as the sample for the current
study, and subsequently represents the largest study to date examining the phenotypic
comorbidity of SUD in AN.
METHODS
Participants
Participants were drawn from the International Price Foundation Genetic Study of AN Trios
sample, which recruited male and female probands affected with AN from nine sites in North
America and Europe. Self-report, clinical, and blood sample data were collected on affected
probands. The study was approved by the appropriate ethical review boards and all participants
completed written informed consent before participation. A detailed description of the study
design is described elsewhere.15
For the current study, only female participants were included as the number of males was too
small for independent analysis or for inclusion as a control for sex effects, resulting in a final
sample size of N = 731. Data on eating disorders and substance use were collected from self-
report and clinical assessments. Blood sample data were not used.
Measures
Demographic and Clinical Variables—Demographic information included age at time
of interview, duration of eating disorders, and highest and lowest self-reported lifetime body
mass index (BMI kg/m2).
Eating Disorder Diagnosis—Modified lifetime history of eating disorders (i.e.,
amenorrhea criterion not required) was assessed using the Structured Inventory of Anorexia
Nervosa and Bulimic Syndromes (SIAB-EX), a semi-structured clinical interview designed to
establish DSM-IV and ICD-10 eating disorder diagnoses 16 and with an expanded version of
Module H of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).17
Information regarding recovery status was obtained from the SCID and information regarding
presence or absence of component features of eating disorder psychopathology (e.g., restrained
eating, binge eating, purging) was obtained from the SIAB-EX.
Participants were classified into one of four AN diagnostic subgroups based on lifetime history:
(1) AN – restricting (RAN) - restricted food intake without purging behavior; (2) AN –purging
(PAN) - met diagnostic criteria for AN and reported purging behavior without binge eating;
(3) AN - binge eating (BAN) - met criteria for AN and reported binge eating with or without
purging; and (4) AN - bulimia nervosa (ANBN) - lifetime history of AN and normal weight
BN.
In addition to diagnostic subtypes, we assessed the relation between SUD and purging behavior
by dividing the sample by presence or absence of lifetime purging as determined by responses
to the SCID and SIAB-EX. Individuals defined as reporting lifetime purging reported engaging
in vomiting, or use of enemas, ipecac, laxatives, and/or diuretics at the subthreshold (less than
twice a week) or threshold level (at least twice a week for at least three months).
Substance Use—Lifetime alcohol abuse and dependence were assessed using the SCID.
18 Two groups were created based on DSM-IV criteria for alcohol abuse or dependence:19 (1)
no alcohol abuse/dependence; and (2) alcohol abuse/dependence.
Lifetime drug abuse and dependence were assessed using the following categories of items
from the SCID: cannabis, sedatives, stimulants, opiates, hallucinogens, cocaine, and other
substances. Abuse and dependence were assessed if participants reported using a substance
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more than 10 times per month (no duration criterion required). Three groups were created: (1)
those who reported never having tried drugs or only having tried a substance once were
classified in the “no use or experimenters” group; (2) those engaging in drug use more than 5
times but not meeting DSM-IV criteria for abuse/dependence were categorized in the “drug
use” group; and, (3) individuals meeting criteria for drug abuse or dependence were categorized
in the “drug abuse/dependence” group.
Statistical Analyses
Analyses were conducted using SAS version 9.1 20, 21 with the GENMOD procedure. Age at
time of interview was entered as a covariate. Prevalence of substance use was calculated across
AN subtypes. Logistic regression analysis was used to test for significant differences in
prevalence of substance use across AN subtypes. Substance use was examined with reference
to purging status and binge eating status. All reported p-values were adjusted for multiple
testing using the method of false discovery rate.22
RESULTS
Demographic Variables
Table 1 describes the demographic variables across AN subtypes. Participants ranged in age
from 13–58 years with a mean age of 26.7 years. The mean for highest BMI ranged from 20.9
to 22.9 kg/m2 and the mean for lowest BMI ranged from 13.5 to 14.4 kg/m2. Participants in
the RAN group were the youngest at the time of interview (i.e., 24.7 years) and those in the
ANBN group were the oldest at time of interview (i.e., 28.5 years). Average eating disorder
duration was longest for those in the ANBN group (i.e., 11.2 years) and shortest for those in
the RAN group (i.e., 7.7 years).
Eating Disorder Subtypes
The RAN group (n = 328) comprised 44.9% of the sample, the PAN group (n = 184) comprised
25.2% of the sample, 14.9% was comprised of the BAN (n = 109) group, and 15.0% of the
sample was comprised of the ANBN group (n = 110).
Substance Use across AN Subtypes
Table 2 presents prevalence of alcohol and drug use and abuse/dependence across AN subtypes
and, due to space limitations, Table 3 presents only the statistically significant odds ratios for
AN subtypes pairwise comparisons.
Alcohol Use—Across the total sample, 19.8% met criteria for lifetime history of alcohol
abuse/dependence. Prevalence was highest in ANBN (35.5%) and lowest in RAN (13.7%).
Risk for alcohol abuse/dependence was 3.20 times greater in the ANBN group and 1.85 times
greater in the BAN group than the RAN group. Risk for alcohol abuse/dependence was 2.24
times greater in the ANBN group compared with the PAN group (χ2 (3, N = 725) = 20.29, p <
0.001).
Drug Use—Across the total sample, 25.9% reported lifetime drug use and an additional 13.8%
met criteria for lifetime history of drug abuse/dependence. The RAN group had the lowest
percentage of drug use (i.e., 23.2%) and drug abuse/dependence (i.e., 6.4%), the PAN group
had the highest percentage of drug use (i.e., 29.9%), and the ANBN group had the highest
percentage of drug abuse/dependence (31.8%; Table 2).
Across AN subtypes, statistically significant differences emerged in the proportion of
individuals meeting criteria for drug use, χ2 (3, N = 730) = 37.62, p < 0.001. Individuals in the
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ANBN group were 1.93 times more likely to report any drug use in comparison to individuals
in the RAN group. The risk for drug abuse/dependence was 6.25 times greater in individuals
with ANBN, 2.84 times greater in individuals with BAN, and 2.27 times greater in individuals
with PAN, compared with those in the RAN group. Also, risk for drug abuse/dependence was
2.78 and 2.17 times greater in those with ANBN compared to those with PAN and BAN,
respectively.
Drug Use Category—Table 2 presents the prevalence for each drug category across AN
subtypes. Because abuse/dependence prevalence was low for the drug categories across
subtypes, we combined the drug use and abuse/dependence into one group. Across AN
subtypes, cannabis was the most frequently reported drug used. Analyses revealed statistically
significant differences in all drug use categories across AN subtypes (Table 2).
AN subtypes pairwise comparison odds ratio by drug use category are presented in Table 3.
Risk for all drug use categories was greatest in the ANBN group and lowest in the RAN group.
Those in the ANBN group were 6.55 times more likely to report stimulant use, 5.89 times more
likely to report cocaine use, 4.72 times more likely to report sedative use, and 5.44 times more
likely to report ‘other’ drug use compared to those in the RAN group. See Table 3 for a complete
list of all pairwise comparisons.
Substance Use by Lifetime Purging Status
Table 4 presents prevalence and odds ratios of substance use by purging status. Lifetime
purging behavior was endorsed by 53.5% of the sample. Lifetime purging was associated with
greater alcohol abuse/dependence, χ2 (1, N = 720) = 9.70, p = 0.002. Those in the purging
group were 1.83 times as likely to meet criteria for alcohol abuse/dependence compared to the
no purging group. The relation between drug abuse/dependence and purging behavior was also
statistically significant, χ2 (1, N = 725) =32.25, p < 0.001, with those in the purging group 1.67
times more likely to be at risk for drug use and 3.79 times more likely to meet criteria for drug
abuse/dependence compared to the no purging group.
Substance Use by Lifetime Binge Eating Status
Table 5 presents prevalence of substance use by lifetime binge eating status. The relation
between substance use categories and binge eating was examined by creating a binge-eating
grouping variable: (1) no history of binge eating (n = 522; 71.4% of the sample); (2) history
of binge eating at low weight (n = 151; 20.6% of the sample); and (3) history of binge eating
only at normal weight (i.e., not during an episode of AN; n = 22; 3.0% of the sample).
Statistically significant differences (χ2 (2, N = 689) =10.85, p = 0.005) emerged across the
binge eating groups for alcohol abuse/dependence. Compared to the no binge eating group,
risk for alcohol abuse/dependence was 1.99 times more likely in the binge eating at low weight
group. No significant differences in alcohol abuse/dependence were found for the binge eating
at low weight group and the binge eating at normal weight group.
Those in the binge eating at low weight group were approximately 2.79 times more likely to
report drug abuse/dependence and those in the binge eating at normal weight group were 4.03
times more likely to report drug use compared with the no history of binge eating group (χ2
(2, N = 668) =14.54, p = 0.001). There were no statistically significant differences for drug use
between the two binge eating groups.
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This is the first study to examine the comorbidity between alcohol and drug use disorders and
AN by investigating the prevalence of SUD across AN subtypes, by comparing individuals
who report binge eating in the underweight state versus those who develop binge eating at
normal weight (i.e., not during episodes of AN), and across the entire sample stratified by the
presence of binge eating and purging. Our findings indicate that: (1) SUD are most common
among individuals with the ANBN subtype; (2) those who endorse purging behavior have
higher rates of SUD compared to those who do not report purging; and (3) prevalence of drug
use differs across binge eating status.
While our observed prevalence of SUD was higher than other AN samples,3, 9, 10, 23–25 which
could be explained by definitional issues (i.e., we used a subthreshold, broader definition for
SUD) or cross-cultural differences in SUD — our findings are consistent with several previous
studies reporting that individuals with BN or with a history of bulimic symptoms during the
course of AN were more likely to report SUD compared to those with RAN.8–11, 26–30
Specifically, in the current study, ANBN participants reported significantly higher levels of
drug abuse/dependence than all other AN subtypes, while the RAN group had the lowest
prevalence of drug abuse/dependence. This finding supports previous research suggesting that
ratio of alcohol abuse/dependence across a sample of inpatient females with BN, ANBN, and
RAN was 9:5:1,10 as well as findings from a community sample with Canadian adolescents
reporting that binge eaters, particularly those who compensated, were more likely to report
substance use.26 Likewise, dietary restraint and bulimic symptoms in Latina adolescents were
positively correlated with alcohol, tobacco and illicit drug use.29 Our finding that greater
substance use occurred in the purging group suggests that there may be meaningful
characteristics associated with classification based on the presence or absence of purging. 12,
13 We also examined the relation of drug category across AN subtypes and found differences
in the prevalence of the drug use category across AN subtypes. In the current study, the most
frequently used drug was cannabis, followed by hallucinogens. These findings support previous
research suggesting that greater pathological eating behavior is associated with not just alcohol
and tobacco but also marijuana and other hard substances.26 The prevalence of cannabis use
being the highest is consistent with population norms 31 and previous research suggesting that
cannabis is the most frequently reported illicit drug among those with restricting and binge
eating/purging symptomatology. 8–11 Our findings are not surprising given that
epidemiological data indicate that cannabis is the most frequently reported illicit drug.31 What
is surprising is that results from this study challenge the commonly held belief that individuals
with RAN report lower levels of drug use.3 Nonetheless it is important to note that the
prevalence reported in this paper may partly reflect normative experimentation with alcohol,
tobacco, and illicit substances, particularly during adolescence and young adulthood.
Therefore, results should be interpreted with caution. Unexpectedly, hallucinogen use was the
second most commonly reported substance used among those with RAN. While little research
exists on the relation between hallucinogen use and eating disorder symptoms, it is possible
that the appetite-suppressing effect of hallucinogens, 32 along with the physiological response
of changes in perceptions and thoughts which might allow one to “escape” the anxiety
associated with the eating disorder, are motivating factors among those who restrict food intake.
These motivations may be further encouraged given the availability of some hallucinogens on
the internet.33
Elaborating on the association between SUD and AN within the current study, findings also
suggest that a higher prevalence of individuals in the BAN and ANBN groups reported greater
sedative, stimulant and cocaine use compared to those in the RAN group, with those in the
ANBN reporting the greatest use. This finding supports previous research suggesting that
cocaine and amphetamine use is greater primarily in individuals with the binge eating/purging
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subtype of AN.30 The use of stimulants and cocaine among the BAN and ANBN groups may
be due to the appetite suppressant effects these drugs may have; thus, their use may be an effort
to avoid the consequences of overeating. It has also been hypothesized that an association
between SUD and eating disorders reflects an underlying influence of personality traits such
as heightened impulsivity.34, 35 Our study was not, however, designed to identify mechanisms
underlying the relation between SUD and binge eating/purging AN.
Of final note, our findings suggest that binge eating was related to substance use under certain
conditions. Risk for alcohol abuse/dependence and drug abuse/dependence was higher in those
who reported binge eating at low weight relative to those who did not binge eat, but differences
did not emerge between those who binge ate at low weight versus binge ate only after weight
restoration. These findings are inconsistent with previous research suggesting that risk for
excessive alcohol consumption is higher in individuals who exhibit binge eating at low weight
compared to those who develop binge eating after restoration of normal weight.6 This
inconsistency could be due to differences across study design (i.e., longitudinal vs. cross-
sectional), and to our smaller sample size. It has also been suggested that reward
hypersensitivity may be a common vulnerability factor for both hazardous drinking and
disordered eating.36–38
Limitations
Limitations to our study must be considered. First, participants are primarily of European
ancestry and therefore cannot be generalized to other ancestry groups or to males. Second, a
healthy comparison group was not available for comparison and our primary interest was
examining differences in SUD across the AN subtypes. Third, we did not make distinctions
between current and lifetime diagnoses for AN. It is possible that differences in substance use
patterns would have emerged had such information been available. Fourth, substance use data
also focused on lifetime use only, not frequency and duration of use which could differentiate
AN subgroups in unique ways. Additionally, the categorization of drug use is a potential
limitation in that the “drug use” group included those who used a substance at least twice but
not enough to meet criteria for abuse/dependence. Thus, results related to the “drug use” group
need to be interpreted given this knowledge. Finally, causal conclusions pertaining to the
development of either eating disorders or SUD cannot be discussed. The nature of any casual
relation between AN and SUD is unknown, thus we are unable to ascertain if the eating disorder
lead to SUD or if the SUD lead to eating disorder symptomatology. Further, we are not aware
if certain substances were specifically used for weight-loss. Additional unexamined factors
may have influenced findings. Of particular relevance are data suggesting that depression,
negative affect, and anxiety are associated with eating disorders and SUD.39, 40 Future studies
should consider depression, negative affect, and anxiety as each relates to the comorbidity of
eating disorders and SUD.
Conclusions and Implications
Results from this and other studies highlight the need to assess alcohol and drug use behavior
when screening and treating individuals with AN, particularly those with bulimic
symptomatology. Our findings support previous research indicating that individuals with
lifetime diagnoses of both AN and BN (ANBN group in the current analysis) and those who
engage in bulimic behaviors report more alcohol abuse/dependence and drug abuse/
dependence than those who only engage in restricting behaviors. These findings are of clinical
importance because prior research indicates that individuals presenting with both an eating
disorder and SUD may be at heightened risk for physical health complications, including
increased lethality,41 and additional psychological comorbidities.7 Given the comorbidity
between AN and SUD, particularly among those with ANBN and BAN, it would appear
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prudent and necessary to combine prevention and treatment efforts in order to better avert the
emergence or advancement of these disorders.
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Table 1













Age at interview (years) 24.7 (7.4) 26.4 (7.0) 27.5 (8.5) 28.5 (8.8)
Highest lifetime BMI (kg/m2) 20.9 (2.3) 21.3 (2.4) 21.0 (2.2) 22.9 (2.1)
Lowest lifetime BMI (kg/m2) 13.5 (1.8) 13.8 (1.9) 13.5 (2.0) 14.4(1.8)
Eating disorder duration (years) 7.7 (6.7) 9.5 (6.7) 10.2 (8.6) 11.2 (8.9)
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Table 3
Statistically Significant Odds Ratios for Alcohol Abuse/Dependence, Drug Use, Drug Abuse/Dependence, and
Drug Use by Drug Category by AN subtypes.
Substance AN subtypes comparison Odds Ratio (95% CI)
Alcohol
Alcohol Abuse/Dependence BAN > RAN 1.85 (1.80, 2.00)
Alcohol Abuse/Dependence ANBN > RAN 3.20 (1.92, 5.33)
Alcohol Abuse/Dependence ANBN > PAN 2.24 (1.30, 3.84)
Drug Use and Drug Abuse/dependence
Drug Use (no abuse/dependence) ANBN > RAN 1.93 (1.13, 3.29)
Drug Abuse/Dependence PAN > RAN 2.27 (1.22, 4.17)
Drug Abuse/Dependence BAN > RAN 2.84 (1.47, 5.56)
Drug Abuse/Dependence ANBN > RAN 6.25 (3.45, 11.11)
Drug Abuse/Dependence ANBN > PAN 2.78 (1.53, 5.00)
Drug Abuse/Dependence ANBN > BAN 2.17 (1.14, 4.17)
Drug Use by Drug Category
Sedatives* BAN > RAN 3.69 (1.54, 8.79)
Sedatives* ANBN > RAN 4.72 (2.06, 10.81)
Cannabis* ANBN > RAN 2.82 (1.79, 4.43)
Cannabis* ANBN > PAN 2.17 (1.33, 3.52)
Cannabis* ANBN > BAN 2.04 (1.18, 3.51)
Stimulants* BAN > RAN 4.00 (1.62, 9.34)
Stimulants* ANBN > RAN 6.55 (2.84, 15.12)
Stimulants* ANBN > PAN 3.05 (1.38, 6.74)
Opiates* BAN > RAN 3.76 (1.50, 9.39)
Opiates* ANBN > RAN 3.64 (1.44, 9.15)
Cocaine* PAN > RAN 2.78 (1.27, 6.09)
Cocaine* BAN > RAN 3.51 (1.51, 8.15)
Cocaine* ANBN > RAN 5.89 (2.21, 10.85)
Hallucinogens* ANBN > RAN 3.51 (1.91, 6.46)
Hallucinogens* ANBN > PAN 2.09 (1.12, 3.92)
Hallucinogens* ANBN > BAN 2.19 (1.05, 4.56)
Other* PAN > RAN 2.94 (1.30, 6.64)
Other* ANBN > RAN 5.44 (2.38, 12.42)
Other* ANBN > BAN 2.62 (1.04, 6.61)
*
Drug use by drug category is defined as having used the substance more than once regardless of abuse or dependence. Only endorsement values are
listed.
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Table 4












9.70 (.002)No Abuse/dependence 287 (85.7) 290 (75.1) -----
Abuse/dependence 48 (14.3) 96 (24.9) 1.83(1.24, 2.70)
Drug Use
32.25 (<.001)
No use/experimenters 238 (70.6) 199 (51.2) -----
Use 77 (22.9) 112 (28.8) 1.67
*
(1.18, 2.37)




Comparisons are made with respect to the No use/experimenters group.
Note. Dashes indicate reference group.
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